Spots Global Cancer Trial Database for A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Official Title: Capturing Canadian Real-World Data for AML Chemotherapy Ineligible Patients on Venetoclax (LIVEN)
Study ID: NCT05424562
Conditions
Interventions
Study Description
Brief Summary: Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax works to treat AML in adult participants who are ineligible for intensive induction chemotherapy in Canada. Venetoclax is a drug approved to treat Acute Myeloid Leukemia (AML). All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive induction chemotherapy will be enrolled. Around 270 participants will be enrolled in the study in approximately 15 sites in Canada. Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 36 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 36 months.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tom Baker Cancer Centre /ID# 248113, Calgary, Alberta, Canada
University of Alberta Hospital /ID# 251531, Edmonton, Alberta, Canada
BC Cancer - Surrey /ID# 257515, Surrey, British Columbia, Canada
Vancouver General Hospital /ID# 245438, Vancouver, British Columbia, Canada
BC Cancer - Victoria /ID# 257339, Victoria, British Columbia, Canada
CancerCare Manitoba /ID# 246414, Winnipeg, Manitoba, Canada
The Moncton Hospital /ID# 247277, Moncton, New Brunswick, Canada
Eastern Regional Health Authority /ID# 250241, St. John's, Newfoundland and Labrador, Canada
QEII - Health Sciences Centre /ID# 246514, Halifax, Nova Scotia, Canada
Juravinski Cancer Centre /ID# 247183, Hamilton, Ontario, Canada
Kingston Health Sciences Centre /ID# 253439, Kingston, Ontario, Canada
London Health Sciences Center- University Hospital /ID# 248027, London, Ontario, Canada
Lakeridge Health - Oshawa /ID# 246412, Oshawa, Ontario, Canada
Thunder Bay Regional Research Institute /ID# 249163, Thunder Bay, Ontario, Canada
Sunnybrook Health Sciences Ctr /ID# 251966, Toronto, Ontario, Canada
Princess Margaret Cancer Centre /ID# 249607, Toronto, Ontario, Canada
Royal Victoria Hospital / McGill University Health Centre /ID# 249704, Montreal, Quebec, Canada
CIUSSS de l'Estrie - CHUS /ID# 248915, Sherbrooke, Quebec, Canada
Allan Blair Cancer Centre /ID# 247663, Regina, Saskatchewan, Canada
Saskatoon Cancer Centre /ID# 247181, Saskatoon, Saskatchewan, Canada
Contact Details
Name: ABBVIE INC.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
